Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer

Breast Cancer

Volumn 9, Issue 3, 2002, Pages 240-247

  Kim, Ryungsa ^a   Osaki, Akihiko ^a   Hirai, Toshihiro ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anthracyclines; Breast cancer; MDR; Tc SESTAMIBI; Vinca alkaloids

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; DRUG RESISTANCE; EPIDEMIOLOGY; FEMALE; HUMAN; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME; VINCA ALKALOIDS;

EID: 0036364621     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967596     Document Type: Article

References (29)

1. Gibbons RJ, Verani MS, Behrenbeck T, et al: Feasibility of tomographic Tc-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 80:1277-1286, 1989. (Pubitemid 19282516)
2. Franceschi M, Guimond J, Zimmerman RE, et al: Myocardial clearance of Tc-99m hexakis-2-methoxy-2-methylpropyl isonitrile (MIBI) in patients with coronary artery disease. Clin Nucl Med 15:307-312, 1990. (Pubitemid 20169064)
3. Savi A, Gerundini P, Zoli P, et al: Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. EurJ Nucl Med 15:597-600, 1989. (Pubitemid 19236001)
4. Endicott JA, and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171, 1989. (Pubitemid 19172967)
5. Roninson IB, ed: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Publishing Corp, New York: 1991.
6. Croop JM, Guild BC, Gros P, et al: Genetics of multidrug resistance: relationship of a cloned gene to the complete multidrug resistant phenotype. Cancer Res 47:5982-5988, 1987. (Pubitemid 18018741)
7. Cole SP, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994. (Pubitemid 24375226)
8. Piwnica-Worms D, Chiu ML, Budding M, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-984, 1993. (Pubitemid 23087894)
9. Hendrikse NH, Franssen EJ, van-der-Graaf WT, et al: 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance associated protein. BrJ Cancer 77:353-358, 1998. (Pubitemid 28044036)
10. Wosikowski K, Regis JT, Robey RW, et al: Normal p53 status and function despite the development of drug resistance in human breast cancer. Cell Growth Differ 6:1395-1403, 1995.
11. Wang H, Mohammad RM, Werdell J, et al: p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostain 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. IntJMol Med 1:915-923, 1998.
12. Orlandi L, Bearzatto A, Abolafio G, et al: Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. Br J Cancer 81:252-260, 1999. (Pubitemid 29423703)
13. Sumantran VN, Ealovega MW, Nunez G, et al: Overexpression of bcl-Xs sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507-2510, 1995.
14. Sakakura C, Sweeney EA, Shirahama T, et al: Overexpression of bax sensitizes breast cancer MCF-7 cells to cisplatin and etoposide. Surg Today 27:676-679, 1997. (Pubitemid 27456057)
15. Ohi Y, Kim R, Toge T: Overcoming of multidrug resistance by introducing the apoptosis gene, bcl-Xs, into MRP-overexpressing drug resistant cells. Int J Oncol 16:959-969, 2000.
16. Duran Cordobes M, Blanchot C, Delmon-Moingeon JC, et al: Tc-99m MIBI uptake by a series of human benign and malignant breast tumor cells: correlation with MDR gene expression. Abstract of the 6th World Congress of Nuclear Medicine and Biology, Sydney, October, EurJ Nucl Med 21 (Suppl):S8, 1994.
17. Moretti JL, Caglar M, Duran Cordobes M, et al: Can nuclear medicine predict response to chemotherapy ? EurJ Nucl Med 22:97-100, 1995.
18. Kim R, Beck WT: Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 54:4958-4966, 1994.
19. Gaj CL, Anyanwutaku I, Chang YH, et al: Decreased drug accumulation without increased drug effux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem Pharmaco155:1199-1211, 1998. (Pubitemid 28206708)
20. Ford JM and Hair WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199, 1990. (Pubitemid 20291782)
21. Boesch D, Gaveriaux C, Jachez B, et al: In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233, 1991.
22. Hyafil F, Vergely C, Du Vignaud P, et al: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602, 1993. (Pubitemid 23304385)
23. Pierre A, Leonce S, Perez V, et al: Circumvention of P-glycoprotein- mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother Pharmacol 42:454-460, 1998. (Pubitemid 28465208)
24. Sikic BI: Modulation of multidrug resistance: at the threshold.J Clin Oncol 11:1629-1635, 1993. (Pubitemid 23277312)
25. Goldstein LJ: Clinical reversal of drug resistance. Curr Probl Cancer 19:65-124, 1995.
26. Rischin D, Webster LK, Millward MJ, et al: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88:97-101, 1996.
27. Csoka K, Dhar S, Fridborg H, et al: Differential activity of Cremophor EL and paclitaxel in patients’ tumor cells and human carcinoma cell line in vitro. Cancer 79:1225-1233, 1997. (Pubitemid 27118221)
28. Nabholtz JM, Falkson G, Campos D, et al: A phase 11I trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 18:127a (abstr 485), 1999.
29. Pluzanska A, Pienkowski T, Jelic S, et al: Phase III multicenter trial comparing taxol/doxorubicin (AT) vs 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer. Breast Cancer Res Treat 57:30 (abstr 21), 1999.